scholarly journals Cord Blood Transplantation for Primary Refractory Acute Myeloid Leukemia

2014 ◽  
Vol 20 (2) ◽  
pp. S154-S155
Author(s):  
Kosei Kageyama ◽  
Hisashi Yamamoto ◽  
Daisuke Kaji ◽  
Hikari Ota ◽  
Kazuya Ishiwata ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cord Blood ◽  
Myeloid Leukemia ◽  
Cord Blood Transplantation ◽  
Blood Transplantation ◽  
Refractory Acute Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals First Successful Cord Blood Transplantation from the National Marrow Donor Program for Acute Myeloid Leukemia in Japan

2016 ◽  
Vol 5 (1) ◽  
pp. 18-21
Author(s):  
Naomi Kawashima ◽  
Yusuke Kagaya ◽  
Sonoko Kamoshita ◽  
Kyoko Watakabe ◽  
Emi Yokohata ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cord Blood ◽  
Myeloid Leukemia ◽  
Cord Blood Transplantation ◽  
Blood Transplantation ◽  
Acute Myeloid

Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia

Blood ◽  
2004 ◽  
Vol 103 (2) ◽  
pp. 489-491 ◽  
Author(s):  
Jun Ooi ◽  
Tohru Iseki ◽  
Satoshi Takahashi ◽  
Akira Tomonari ◽  
Kashiya Takasugi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cord Blood ◽  
Median Time ◽  
Myeloid Leukemia ◽  
De Novo ◽  
Cord Blood Transplantation ◽  
Adult Patients ◽  
Blood Transplantation ◽  
Unrelated Cord Blood ◽  
Acute Myeloid

Abstract We report the results of unrelated cord blood transplantation (CBT) for 18 adult patients with de novo acute myeloid leukemia (AML). The median age was 43 years, the median weight was 55.2 kg, and the median number of cryopreserved nucleated cells was 2.51 × 107/kg. Seventeen patients had myeloid reconstitution and the median time to more than 0.5 × 109/L absolute neutrophil count was 23 days. A self-sustained platelet count more than 50 × 109/L was achieved in 16 patients at a median time of 49 days. Acute graft-versus-host disease (GVHD) above grade II occurred in 11 of 17 evaluable patients and chronic GVHD occurred in 14 of 17 evaluable patients. Fourteen patients are alive and free of disease at between 185 and 1332 days after transplantation. The probability of disease-free survival at 2 years was 76.6%. These results suggest that adult AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.

Sign in / Sign up

Export Citation Format

Share Document